Large pharmaceutical companies say allowing Medicare to negotiate lower drug prices will stifle innovation in drug development. Read a new op-ed in Harvard Business Review to find out why that’s not so.
Tracking the Vaccine Rollout
Federal and State Efforts to Achieve Speed and Equity
